Opinion
Video
Examining 3-Year Update Data from the CASPIAN Trial
Author(s):
A medical expert discusses the impact of the 3-year overall survival data from the CASPIAN trial on the treatment landscape for extensive-stage small cell lung cancer (ES-SCLC), emphasizing the significance of the long-term follow-up results in shaping the current treatment paradigm.
- Please review the 3-year overall survival update from the CASPIAN trial, assessing durvalumab ± tremelimumab plus platinum-etoposide in the first-line treatment of ES-SCLC, and discuss the impact of these findings on the treatment landscape. (Paz-Ares L, et al. ESMO Open. 2022: 7(2):100408)
- Please comment on how clinical outcomes from this trial have influenced the treatment algorithm for ES-SCLC and the importance of the long-term follow-up data.
- From a clinical perspective, how impactful to you and to your patients with ES-SCLC is the survival rate, which tripled from 6% to 18% at 3 years in the CASPIAN clinical trial?
- With the updated CASPIAN trial outcomes and the endpoints from ADRIATIC, can we now extrapolate the survival benefits with immunotherapy, which apply to all stages of SCLC?
- In the exploratory analysis of the CASPIAN Phase III clinical trial, a similar prevalence of neuroendocrine and non-neuroendocrine subtypes was detected in a subgroup of 104 patients with RNA sequencing data. However, Inflamed or YAP1 subtypes in the durvalumab + etoposide treatment arm experienced the longest overall survival.
- What characteristics of these SCLC subtypes suggest that they may be betterprimed to respond to immunotherapy, and what are some future clinical implications of this finding?
Related Videos
Related Content
